MNKD Investors


One of the largest organs in your body are the lungs. Picture the size of a full tennis court and that is roughly the surface area of both lungs in a typical adult.

NTM Lung Disease on the Rise

“I cough every morning upon waking, so I don’t feel rested.” “Imagine not being able to breathe.” “Anxiety ruins everything about you – it’s not a normal life.” “You just exist from day to day and week to week.”

What exactly is the Technosphere® Platform?

NTM Lung Disease on the Rise

Share & Print option

Release Details

Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone


DANBURY, Conn., June 11, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12. The visit coincides with MannKind reaching a manufacturing milestone as it has successfully scaled-up operations for increased production capacity of Tyvaso DPI®.

Through MannKind’s partnership with United Therapeutics the current expansion project represents a $60 million investment. Construction is ongoing to build out new manufacturing space designed to expand production in anticipation of the continued growth of Tyvaso DPI. In the past two years, MannKind has experienced more than a 250% increase in its Connecticut workforce across manufacturing, R&D and support functions.

  10:00 a.m.11:00 a.m.
  40 Taylor Street (Danbury, CT)
VISUALS/SOUND: - Governor Lamont tours facility with MannKind CEO Dr. Michael Castagna and COO Lauren Sabella
  - Construction underway on “clean rooms” and spray dry equipment in new manufacturing space
  - Demonstration of MannKind’s innovative Technosphere® particle and device technologies
  - Production personnel producing the particle technology used as part of our inhaled insulin (Afrezza®) as well as Tyvaso DPI
MANNKIND: MannKind Corporation focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.

CONTACT:  MannKind Corporate Communications
  Christie Iacangelo (on-site)   
  (818) 292-3500 (mobile) 

Primary Logo

Source: MannKind